Another immunotherapy approach in cancer is based on the redirection of T cells against tumor cells by stable integration of tumor-specific antigen receptors, either with T cell receptors (TCRs) which recognize MHC-presented epitopes from both intra- and extracellular antigens, or CARs which bind to tumor surface antigens and are MHC-independent. This evidence concerns the gene HLA-C and neoplasm.